Additional Details SKU: 0741
Retatrutide has not yet been approved by the FDA
As described in the CY 2026 OPPS/ASC proposed rule, we proposed to strengthen this requirement, beginning January 1, 2026, by replacing it with an attestation in the MRF, and that attestation would also contain new specifications (compared to existing affirmation requirements)
Published Research Data Quantified findings from peer-reviewed studies on BPC-157 + TB-500 + GHK-Cu human genes modulated by GHK-Cu in gene expression analysis increase in collagen synthesis observed in fibroblast cultures treated with GHK-Cu reduction in TNF-alpha inflammatory markers in GHK-Cu treated tissue models HPLC-verified purity range across published Certificates of Analysis collagen and ECM-related genes upregulated by GHK-Cu in connectivity map data Published Research Studies on BPC-157 + TB-500 + GHK-Cu 2018 Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data Int J Mol Sci Review of GHK-Cu gene expression data showing modulation of 4,000+ human genes involved in tissue remodeling, antioxidant defense, and anti-inflammatory pathways
Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
What animals can be treated with Iron Dextran + Vitamin B12 Injection
